H. van Onzenoort

First name

H.

Middle name

A.

Last name

van Onzenoort

Driessen, J. H., van Onzenoort, H. A., Henry, R. M., Lalmohamed, A., van den Bergh, J. P., Neef, C., et al. (2014). Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone. http://doi.org/10.1016/j.bone.2014.07.030

View

Pouwels, S., de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Onzenoort, H. A., & de Vries, F. (2014). Risk of fracture in patients with muscular dystrophies. Osteoporos Int. http://doi.org/10.1007/s00198-013-2442-2

View

Driessen, J. H., Henry, R. M., van Onzenoort, H. A., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., et al. (2015). Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis. Calcif Tissue Int. http://doi.org/10.1007/s00223-015-9993-5

View

Driessen, J. H., van den Bergh, J. P., van Onzenoort, H. A., Henry, R. M., Leufkens, H. G., & de Vries, F. (2017). Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.12843

View